The cost-utility analysis by Hughes et al demonstrated that using adalimumab for treating uveitis in the UK is not cost-effective compared with methotrexate alone.
We wish to address 2 issues: (1) the Health Utilities Index (HUI) III
sensitivity for quantifying ophthalmic quality of life (QOL) and (2)
the discriminatory aspects of multiattribute QOL instruments (the
HUI III and EuroQOL-5D).